Literature DB >> 3497717

Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas.

M A Palladino, P K Srivastava, H F Oettgen, A B DeLeo.   

Abstract

A tumor-specific antigen (TSA) expressed on the chemically induced BALB/c Meth A sarcoma and one of 22 other BALB/c sarcomas tested, CMS13, was detected in in vitro cellular and humoral assays. The distribution pattern of the TSA defined in a complement-dependent microcytoxicity assay by cytotoxic antibodies present in CMS13 antisera was similar to that detected by a cytotoxic T-cell clone, designated CTLL-MA10B, in an 18-h cell-mediated cytotoxicity assay. The serologically defined TSA was shown to be expressed on gp96, a Mr 96,000 glycoprotein isolated from Meth A cytosol with immunoprotective activity in in vivo tumor rejection assays. Immunization of BALB/c mice with Meth A, CMS13, or preparations of gp96 isolated from these sarcomas induced tumor resistance in these mice to Meth A and CMS13 but not CMS5, an antigenically unrelated sarcoma. These results suggest that the shared TSA is expressed on gp96 and is functional in tumor rejection assays.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497717

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94.

Authors:  T J Nieland; M C Tan; M Monne-van Muijen; F Koning; A M Kruisbeek; G M van Bleek
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Glycoprotein (gp) 96 expression: induced during differentiation of intestinal macrophages but impaired in Crohn's disease.

Authors:  K Schreiter; M Hausmann; T Spoettl; U G Strauch; F Bataille; J Schoelmerich; H Herfarth; W Falk; G Rogler
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 4.  Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.

Authors:  Natasa Strbo; Arlene Garcia-Soto; Taylor H Schreiber; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

5.  Fusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo.

Authors:  Honghai Zhang; Weida Huang
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

Review 6.  Heat shock proteins transfer peptides during antigen processing and CTL priming.

Authors:  P K Srivastava; H Udono; N E Blachere; Z Li
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

7.  Purification of heat shock protein 70-associated tumor peptides and their antitumor immunity to hepatoma in mice.

Authors:  Dai-Xiong Chen; Yan-Rong Su; Gen-Ze Shao; Zhen-Chao Qian
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 8.  Heat shock proteins in immune response to cancer: the Fourth Paradigm.

Authors:  P K Srivastava
Journal:  Experientia       Date:  1994-11-30

9.  Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo.

Authors:  H Udono; D L Levey; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

10.  A new purification method for enhancing the immunogenicity of heat shock protein 70-peptide complexes.

Authors:  Yanwei Gao; Xia Chen; Weishi Gao; Yong Yang; Hulin Ma; Xinjun Ren
Journal:  Oncol Rep       Date:  2012-09-21       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.